Table 2.

Patient characteristics

Characteristicn (%)
Age (y), median (range)58 (20-77)
Gender
    Female8 (25)
    Male24 (75)
Diagnosis
    AML27 (84.4)
        Prior MDS or MPD11 (41)
        Treatment related3 (11)
    ALL3 (9.4)
    MDS2 (6.2)
Duration of disease (mo), median (range)9 (0.13-34.8)
ECOG performance status, median1
    012 (37.5)
    112 (37.5)
    28 (25)
Karyotype
    AML/MDS29
        Good, inv16, t(8;21)1 (3.4)*
        Intermediate, normal4 (13.8)
        Poor, 11q23, 5 or 7 anomalies, others21 (72.4)
        Inadequate2 (6.9)
        Not done1 (3.4)
    ALL3
        Normal2 (67)
        Not done1 (33)
Prior therapy
    Median treatment regimens (range)2 (0-7)
    Prior chemotherapy31 (96.9)
    Prior allogeneic stem cell transplant6 (18.8)
Baseline WBC count (×109/L), median (range)3.1 (0.3-42)
Baseline platelet count (×109/L), median (range)18.5 (3-146)
Baseline peripheral blast count (×109/L), median (range)0.22 (0-28.1)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; MPD, myeloproliferative disease.

  • * 48,XX, +6,t(8;21)(q22;q22), +der(21)t(8;21).